A phase 2b double-blind randomised 5-arm vehicle-controlled dose

Recruiting

99 years or below

All

Phase 2

10 participants needed

1 Location

Brief description of study

The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD as defined by the Hanifin and Rajka criteria for AD History of AD for 1 year. AD involvement of 550% treatable body surface area at screening and at baseline Procedures include labs, skin swabs, biopsies, EKG, subject questionnaires (excluding scalp).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 Dec 2019. Study ID: 832268

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.

Brief description of study

Eligibility of study

Find a site